What is Echelon Diagnostics?
Echelon Diagnostics operates at the intersection of big data and clinical healthcare, providing a comprehensive suite of diagnostic and analytical tools. The company's portfolio is anchored by specialized platforms such as PrenatalDx for non-invasive testing, Triton for genomic data integration, and OncDx for oncology characterization. Furthermore, the firm addresses the growing demand for reproductive health solutions through its RefineDx carrier screening systems and CrisprRx gene editing proficiency tools. By integrating these advanced technologies, Echelon Diagnostics enables healthcare organizations to optimize clinical workflows, ensure rigorous FDA compliance, and ultimately improve patient outcomes through highly tailored, data-centric methodologies.
How much funding has Echelon Diagnostics raised?
Echelon Diagnostics has raised a total of $129K across 1 funding round:
Debt
$129K
Debt (2021): $129K with participation from PPP
Key Investors in Echelon Diagnostics
PPP
Public-Private Partnership
What's next for Echelon Diagnostics?
With this latest injection of capital, Echelon Diagnostics is poised to accelerate its operational expansion and deepen its research and development capabilities. The strategic focus will likely shift toward enhancing the interoperability of its genomic data platforms and broadening the commercial reach of its oncology and reproductive health suites. As the healthcare industry increasingly pivots toward personalized medicine, Echelon's ability to synthesize complex biological data into actionable clinical insights will be a primary driver of its long-term competitive advantage. The company is well-positioned to leverage this financing to capture additional market share, refine its regulatory compliance services, and solidify its role as an essential partner for modern, data-informed healthcare providers.
See full Echelon Diagnostics company page
